Is FDA too lax with its drug ap­proval stan­dards? Se­nior FDA of­fi­cials dis­cuss

From in­dus­try to acad­e­mia, com­menters have ar­gued that the FDA drug ap­proval stan­dards are be­com­ing in­ap­pro­pri­ate­ly low and that the re­quired postap­proval eval­u­a­tions are ei­ther …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.